Axicabtagene Ciloleucel

CHEMBL3989989 Phase 4 Approved Gene

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

— g/mol

LogP

—

Phase

4

A CAR-T cell therapy in which a patient's own T cells are genetically engineered to express a chimeric antigen receptor targeting CD19, a protein on the surface of certain B-cell cancers. The modified cells are infused back to seek out and destroy cancer cells.

Therapeutic Areas

Leukemia Lymphoma

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

A CAR-T cell therapy in which a patient's own T cells are genetically engineered to express a chimeric antigen receptor targeting CD19, a protein on the surface of certain B-cell cancers. The modified cells are infused back to seek out and destroy cancer cells.

Yes, Axicabtagene Ciloleucel is an approved drug. It has reached clinical phase 4. It is classified as a Gene.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3989989. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

PillFYI

Looking for patient-friendly information?

Axicabtagene Ciloleucel on PillFYI

Quick Data

Synonyms: 1

External Links

ChEMBL CHEMBL3989989

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.